aVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Electronic address: rtoledo@vhio.net
bVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
cDivision of Hematology and Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
dMays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Electronic address: dahia@uthscsa.edu
eVall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
fMays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
gDivision of Endocrinology, Diabetes, and Hypertension, Center for Adrenal Disorders, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
hDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
The HIF-2α inhibitor belzutifan was recently U.S. Food and Drug Administration (FDA)-approved for advanced pheochromocytoma/paraganglioma. This multistakeholder article calls for clinical-trial genomic correlates and outcome data to clarify efficacy across these molecularly heterogeneous neuroendocrine tumors.
Plain-language summary
Discussion
Department of Endocrinology, Queen Elizabeth Hospital Birmingham NHS Trust, Birmingham, UK
jDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, UK
kAssistance PubliqueHôpitaux de Marseille and Aix-Marseille University, Marseille, France
lDepartment of Endocrinology, MMG, INSERM U1251, Marmara Institute, Hôpital de la Conception, CRMR HYPO, Marseille, France
mCancer Genetics Laboratory, Kolling Institute of Medical Research, Sydney, New South Wales, Australia
nDepartment of Diabetes, Endocrinology Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia
oFaculty of Medicine Health, University of Sydney, Sydney, New South Wales, Australia
pDepartment of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
qCambridge Endocrine Molecular Imaging Group, Wellcome-MRC Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, UK
rDepartment of Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
sDepartment of Genetics, University of Cambridge, Cambridge, UK
tUnidade de Adrenal, Laboratório de Endocrinologia Molecular E Celular LIM25, Divisão de Endocrinologia E Metabologia, Hospital Das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
uUnidade de Oncologia Endócrina, Instituto Do Câncer Do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
vDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA
wNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
xDepartment of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Hospital, and Endocrinology and Adrenal Tumor Center, Tokyo, Japan
yDivision of Endocrinology, Department of Medicine, Centre Hospitalier de l’Université de Montréal Research Center (CRCHUM), Montreal, Quebec, Canada
zEndocrinology Nutrition Department, Hospital Universitario Ramón Y Cajal, Madrid, Spain
aaInstituto de Investigación Biomédica Ramón Y Cajal (IRYCIS), Madrid, Spain
abDepartment of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People’s Republic of China, Beijing, PR China
acPeking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China
adParadifference Foundation, London, UK
aePHEIPAS Pheochromocytoma and Paraganglioma Patients Association, Castellón, Spain
afThe Association for Multiple Endocrine Neoplasia Disorders (AMEND), Tonbridge, UK
agNeuroendocrine Tumor Research Foundation (NETRF), Boston, MA, USA
ahDepartment of Medical Oncology, Division of Cancer Care Services, Princess Alexandra Hospital, Metro South Health Service, Queensland Health, Brisbane, Queensland, Australia
aiSchool of Medicine, University of Queensland, Brisbane, Queensland, Australia
ajDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
akDivision of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA
alDepartment of Endocrinology, St Bartholomew’s Hospital, Barts Health NHS Trust, London, UK
amDepartment of Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, UK
